查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非感染性黃斑水腫治療的全球市場 - 全球產業分析、規模、份額、成長、趨勢和預測（2031） - 按藥物類型、按適應症、按給藥途徑、按分銷管道、按地區
市場調查報告書
商品編碼
1410591

非感染性黃斑水腫治療的全球市場 - 全球產業分析、規模、份額、成長、趨勢和預測（2031） - 按藥物類型、按適應症、按給藥途徑、按分銷管道、按地區

Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 323 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

一項開創性的研究揭示了全球非感染性黃斑水腫治療市場的重大發展。 各地區糖尿病相關併發症的迅速增加以及人們對眼部相關疾病的認識不斷提高，推動了對黃斑水腫有效治療的需求不斷增長。 需求激增導致市場上治療選擇激增，包括抗 VEGF 藥物、皮質類固醇、免疫抑制劑和生物製劑。 抗 VEGF 療法傳統上佔據市場主導地位，預計在預測期內將保持較高的市場份額。

然而，由於人們對抗 VEGF 藥物相關潛在副作用的認知不斷增強，因此預計抗 VEGF 藥物市場的使用量將逐漸下降。 全身性免疫調節治療可減少對抗 VEGF 藥物的依賴。 值得注意的是，未來幾年對皮質類固醇的需求預計將激增，並且市場預計在預測期內將呈指數級增長。

最近核准用於治療黃斑水腫的玻璃體內植入物是市場成長的催化劑。 玻璃體內注射的採用正在增加，特別是在北美，隨著三種新產品的推出：Eylea、Ozurdex 和 Iluvien。 在北美和歐洲國家，直到2012年Lucentis上市之前，玻璃體內注射尚未廣泛使用，雷射光凝固是主要的治療方法。

越來越多地採用玻璃體內注射療法是由於玻璃體內皮質類固醇植入物在低劑量下非常有效。 患者越來越多地使用玻璃體內植入物，推動了全球對黃斑水腫治療的需求。

免疫抑制治療常與皮質類固醇合併使用，在黃斑水腫的治療中扮演重要角色。 這些治療劑通常添加到皮質類固醇治療方案中以減少對大劑量類固醇的需求，或者當類固醇治療不能很好耐受時單獨使用作為類固醇節省劑。

雖然市場顯示出巨大的成長潛力，但挑戰仍然存在。 許多患者和眼科醫師正在選擇替代治療，而不是抗 VEGF 和皮質類固醇藥物。 對於糖尿病黃斑水腫 (DME) 患者，由於錯過注射而不遵守治療計劃可能會導致不可逆的損傷和永久性視力喪失。

此外，全球市場上很容易買到假藥和標籤外藥品。 幾種重磅抗 VEGF 藥物的生物相似藥的推出預計將透過減少品牌和專利藥物的使用來進一步影響市場。

本報告調查了全球非感染性黃斑水腫治療市場，按藥物類型、適應症、給藥途徑、分銷管道、地區和市場參與者提供了市場概述。它提供了資訊企業的競爭趨勢。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第三章2018-2023年生產與貿易統計

第 4 章價格分析，2018-2023

第五章2018-2031年全球非感染性黃斑水腫治療市場前景

  • 全球非感染性黃斑水腫治療市場前景，按藥物類型、價值（百萬美元）和數量（2018-2031 年）劃分
  • 全球非感染性黃斑水腫治療市場前景，按適應症、價值（百萬美元）和數量（2018-2031 年）劃分
  • 全球非感染性黃斑水腫治療市場前景、給藥途徑、價值（百萬美元）和數量（2018-2031 年）
  • 全球非感染性黃斑水腫治療市場展望，依通路、價值（百萬美元）、銷售量（2018-2031 年）
  • 全球非感染性黃斑水腫治療市場展望，按地區、價值（百萬美元）、銷售量（2018-2031 年）

第6章北美非感染性黃斑水腫治療市場前景，2018-2031

第 7 章歐洲非感染性黃斑水腫治療市場前景，2018-2031

第 8 章亞太地區非感染性黃斑水腫治療市場前景，2018-2031

第 9 章拉丁美洲非感染性黃斑水腫治療市場展望，2018-2031

第10章中東及非洲非感染性黃斑水腫治療市場前景，2018-2031

第十一章競爭態勢

  • 產品和指示熱圖
  • 2023 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Pfizer, Inc.
    • Novartis AG
    • F. Hoffman - La Roche Ltd.
    • AbbVie Inc
    • Bayer AG
    • Valeant Pharmaceuticals Inc
    • Alimera Sciences Inc
    • Clearside Biomedical, Inc

第12章附錄

簡介目錄

A groundbreaking study has shed light on a remarkable development in the global non-infectious macular edema treatment market. The surge in diabetes-related complications and increased awareness of eye-related ailments across various regions have fueled a growing demand for effective treatments for macular edema. This surge in demand has led to a proliferation of treatment options in the market, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and more. Anti-VEGF treatments have traditionally dominated the market, and they are expected to maintain the highest market share during the forecast period.

Transition Away from Anti-VEGF Toward Corticosteroids

However, the Anti-VEGF market is anticipated to witness a gradual decline in usage due to heightened awareness of potential side effects associated with the drug. Systemic immunomodulatory treatment is poised to reduce reliance on Anti-VEGF medications. Notably, Corticosteroids are projected to experience an exceptional surge in demand in the coming years, with the market expected to grow at a stellar rate during the forecast period.

Intravitreal Implants and Immunosuppressants Triggering Market Growth

The recent approval of Intravitreal Implants for macular edema treatment has catalyzed market growth. The introduction of three new products - Eylea, Ozurdex, and Iluvien - has led to increased adoption of intravitreal medications, particularly in North America. Intravitreally injected medications were less commonly used in North America and European countries, where laser photocoagulation was the primary treatment method before the launch of Lucentis in 2012.

The rising adoption of Intravitreal therapies can be attributed to the availability of low-dose, high-efficacy corticosteroid implants for Intravitreal use. Patients are increasingly turning to Intravitreal implants, driving global demand for macular edema treatment.

Immunosuppressant Therapies Enhance Treatment Efficacy

Immunosuppressant therapies, often used in conjunction with corticosteroids, play a vital role in the treatment of macular edema. These therapies are typically added to corticosteroid regimens to reduce the need for high doses of systemic steroids or used independently as steroid-sparing agents when steroid treatment is not well-tolerated.

For example, three immunomodulators - methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate mofetil (MMF, Cellcept) - have proven to be highly effective in achieving disease quiescence and are well-tolerated by patients. These immunosuppressants have emerged as efficient treatment options, driving demand in the global market for non-infectious macular edema treatment.

Challenges in the Global Macular Edema Market

While the market exhibits significant growth potential, challenges persist. Many patients and ophthalmologists opt for alternative treatments over Anti-VEGF and corticosteroids due to the repeated injections and high costs associated with these drugs. Non-compliance with treatment schedules, resulting in missed injections, can lead to irreversible damage and permanent vision loss in diabetic macular edema (DME) patients.

Additionally, counterfeit and off-label drugs are readily available in the global market. The launch of biosimilars for some blockbuster anti-VEGF agents is expected to further impact the market by reducing opportunities for branded and patented drugs.

Market Segmentation

Drug Type

  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressant
  • Biologics
  • Others

Indication

  • Non-infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • Japan
  • MEA
  • APAC

Table of Contents

1. Executive Summary

  • 1.1. Global Non-infectious Macular Edema Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Non-infectious Macular Edema Treatment Market Production Output, by Region, Value (US$ Mn), 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2018 - 2023
  • 4.2. Prominent Factor Affecting Non-infectious Macular Edema Treatment Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 5.1. Global Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Anti-VEGF
      • 5.1.1.2. Corticosteroids
      • 5.1.1.3. Immunosuppressant
      • 5.1.1.4. Biologics
      • 5.1.1.5. Others
  • 5.2. Global Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Non-infectious Uveitic Macular Edema
      • 5.2.1.2. Diabetic Macular Edema
      • 5.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 5.3. Global Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Parenteral
      • 5.3.1.3. Topical
  • 5.4. Global Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
  • 5.5. Global Non-infectious Macular Edema Treatment Market Outlook, by Region, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 6.1. North America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Anti-VEGF
      • 6.1.1.2. Corticosteroids
      • 6.1.1.3. Immunosuppressant
      • 6.1.1.4. Biologics
      • 6.1.1.5. Others
  • 6.2. North America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Non-infectious Uveitic Macular Edema
      • 6.2.1.2. Diabetic Macular Edema
      • 6.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 6.3. North America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Parenteral
      • 6.3.1.3. Topical
  • 6.4. North America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
  • 6.5. North America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.2. U.S. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.3. U.S. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.4. U.S. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.5. Canada Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.6. Canada Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.7. Canada Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.8. Canada Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 7.1. Europe Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Anti-VEGF
      • 7.1.1.2. Corticosteroids
      • 7.1.1.3. Immunosuppressant
      • 7.1.1.4. Biologics
      • 7.1.1.5. Others
  • 7.2. Europe Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Non-infectious Uveitic Macular Edema
      • 7.2.1.2. Diabetic Macular Edema
      • 7.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 7.3. Europe Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Parenteral
      • 7.3.1.3. Topical
  • 7.4. Europe Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
  • 7.5. Europe Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.2. Germany Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.3. Germany Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.4. Germany Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.5. U.K. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.6. U.K. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.7. U.K. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.8. U.K. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.9. France Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.10. France Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.11. France Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.12. France Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.13. Italy Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.14. Italy Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.15. Italy Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.16. Italy Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.17. Turkey Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.18. Turkey Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.19. Turkey Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.20. Turkey Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.21. Russia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.22. Russia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.23. Russia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.24. Russia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.25. Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.26. Rest of Europe Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.27. Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.28. Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Anti-VEGF
      • 8.1.1.2. Corticosteroids
      • 8.1.1.3. Immunosuppressant
      • 8.1.1.4. Biologics
      • 8.1.1.5. Others
  • 8.2. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Non-infectious Uveitic Macular Edema
      • 8.2.1.2. Diabetic Macular Edema
      • 8.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 8.3. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Parenteral
      • 8.3.1.3. Topical
  • 8.4. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
  • 8.5. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. China Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.2. China Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.3. China Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.4. China Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.5. Japan Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.6. Japan Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.7. Japan Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.8. Japan Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.9. South Korea Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.10. South Korea Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.11. South Korea Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.12. South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.13. India Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.14. India Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.15. India Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.16. India Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.17. Southeast Asia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.18. Southeast Asia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.19. Southeast Asia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.20. Southeast Asia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.21. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.22. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.23. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.24. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 9.1. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Anti-VEGF
      • 9.1.1.2. Corticosteroids
      • 9.1.1.3. Immunosuppressant
      • 9.1.1.4. Biologics
      • 9.1.1.5. Others
  • 9.2. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Non-infectious Uveitic Macular Edema
      • 9.2.1.2. Diabetic Macular Edema
      • 9.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 9.3. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Parenteral
      • 9.3.1.3. Topical
  • 9.4. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospital Pharmacies
      • 9.4.1.2. Retail Pharmacies
      • 9.4.1.3. Online Pharmacies
  • 9.5. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.2. Brazil Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.3. Brazil Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.4. Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.5. Mexico Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.6. Mexico Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.7. Mexico Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.8. Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.9. Argentina Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.10. Argentina Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.11. Argentina Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.12. Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.13. Rest of Latin America Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.14. Rest of Latin America Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.15. Rest of Latin America Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.16. Rest of Latin America Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Anti-VEGF
      • 10.1.1.2. Corticosteroids
      • 10.1.1.3. Immunosuppressant
      • 10.1.1.4. Biologics
      • 10.1.1.5. Others
  • 10.2. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Non-infectious Uveitic Macular Edema
      • 10.2.1.2. Diabetic Macular Edema
      • 10.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 10.3. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Parenteral
      • 10.3.1.3. Topical
  • 10.4. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospital Pharmacies
      • 10.4.1.2. Retail Pharmacies
      • 10.4.1.3. Online Pharmacies
  • 10.5. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.2. GCC Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.3. GCC Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.4. GCC Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.5. South Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.6. South Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.7. South Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.8. South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.9. Egypt Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.10. Egypt Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.11. Egypt Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.12. Egypt Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.13. Nigeria Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.14. Nigeria Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.15. Nigeria Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.16. Nigeria Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.17. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.18. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.19. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.20. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. Product vs Indication Heatmap
  • 11.2. Company Market Share Analysis, 2023
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Pfizer, Inc.
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. Novartis AG
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. F. Hoffman - La Roche Ltd.
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. AbbVie Inc
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. Bayer AG
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. Valeant Pharmaceuticals Inc
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Alimera Sciences Inc
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Clearside Biomedical, Inc
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations